Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CPL207280 in Healthy Volunteers
NCT04622111Phase 1Completed
- Sponsor
- Celon Pharma S.A.
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CPL207280 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Celon Pharma S.A. Primary endpoints: Maximum Tolerated Dose and Safety and Tolerability. Started May 2020; status: completed.
02
Drugs
CPL207280
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04622111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622111.